Q-omics provides the consensus-scored NICN1 profile across patient tissues and cancer cell-line models. NICN1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NICN1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NICN1 RNA expression shows 19,757 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where NICN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NICN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NICN1 survival associations across molecular data types. NICN1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NICN1 RNA expression–survival associations across cancer types. High NICN1 expression shows unfavorable associations in LIHC, but favorable associations in UVM, KIRP, HNSC, READ and MESO. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NICN1 RNA expression.
This table summarizes NICN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NICN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NICN1 shows lower tumor expression in KIRC, THCA, HNSC, KICH, LUSC and LUAD. The KIRC box plot shows higher NICN1 RNA expression in normal versus tumor tissue (log2 FC = −1.304, t-test p < 0.001).
This table shows molecular features associated with NICN1 in patient tissues and cancer cell lines. In patient samples, NICN1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NICN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
